Clinical Trials Logo

Filter by:
NCT ID: NCT00724503 Completed - Colorectal Cancer Clinical Trials

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

SIRFLOX
Start date: August 2006
Phase: N/A
Study type: Interventional

This study is a randomized multi-center trial that will assess the effect of adding Selective Internal Radiation Therapy (SIRT), using SIR-Spheres microspheres®, to a standard chemotherapy regimen of FOLFOX as first line therapy in patients with non-resectable liver metastases from primary colorectal adenocarcinoma. Treatment with the biologic agent bevacizumab, if part of the standard of care at participating institutions, is allowed within this study at the discretion of the treating Investigator.

NCT ID: NCT00723957 Completed - Clinical trials for Advanced/Metastatic Non-Small Cell Lung Cancer

A Randomized Phase 2 Study of Ixabepilone Plus Carboplatin and Paclitaxel Plus Carboplatin in Advanced Nonsmall-Cell Lung Cancer

Start date: December 2008
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether progression-free survival with ixabepilone is superior to that achieved with paclitaxel plus carboplatin in participants with advanced nonsmall-cell lung cancer and beta III (βIII)-tubulin-positive tumors.

NCT ID: NCT00722046 Completed - Alzheimer's Disease Clinical Trials

Multiple IV Dose Study Of PF-04360365 In Patients With Mild To Moderate Alzheimer's Disease

Start date: December 5, 2008
Phase: Phase 2
Study type: Interventional

Purpose of the study is to determine whether multiple dose administration of PF-04360365 is safe and well tolerated in patient with mild to moderate Alzheimer's disease.

NCT ID: NCT00721123 Completed - Clinical trials for Rheumatoid Arthritis

A Long-term Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients With Rheumatoid Arthritis

Start date: August 2005
Phase: Phase 3
Study type: Interventional

This open-label, international multi-center extension study WA18695 was designed to assess the long term safety of tocilizumab in patients who had moderate to severe active rheumatoid arthritis (RA). Patients enrolled in the WA18695 study had previously received treatment in the 24-week, placebo-controlled, Phase III Study WA17822. Eligible patients were assigned to treatment with 8 mg/kg tocilizumab every 4 weeks for a maximum of 5 years.

NCT ID: NCT00720941 Completed - Clinical trials for Carcinoma, Renal Cell

Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma

COMPARZ
Start date: August 14, 2008
Phase: Phase 3
Study type: Interventional

This study is being conducted to provide a direct comparison of the efficacy, safety and tolerability for pazopanib and sunitinib (SUTENT)

NCT ID: NCT00720798 Completed - Clinical trials for Rheumatoid Arthritis

An Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients Completing Treatment in Tocilizumab Core Studies

Start date: September 2005
Phase: Phase 3
Study type: Interventional

This single-arm study evaluated the long-term efficacy and safety of tocilizumab in participants who had completed treatment in the tocilizumab core studies (NCT00106522 [Roche protocol WA18062], NCT00106574 [Roche protocol WA18063], and NCT00109408 [Roche protocol WA17824]) of adults with rheumatoid arthritis. Participants received tocilizumab alone or in combination with standard anti-rheumatic treatment.

NCT ID: NCT00720109 Completed - Clinical trials for Acute Lymphoblastic Leukemia

Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Start date: July 14, 2008
Phase: Phase 2/Phase 3
Study type: Interventional

This phase II/III trial is studying the side effects and how well giving dasatinib together with combination chemotherapy works in treating young patients with newly diagnosed acute lymphoblastic leukemia (ALL). Dasatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving dasatinib together with combination chemotherapy may kill more cancer cells.

NCT ID: NCT00718861 Completed - Clinical trials for Post-menopausal Osteoporosis

3 yr Efficacy & Safety Study of Zoledronic Acid in Post-menopausal Women With Osteoporosis Treated With Zol Acid for 6 Yrs

Start date: May 2008
Phase: Phase 3
Study type: Interventional

This second extension will evaluate the efficacy and long term safety of zoledronic acid in women with post-menopausal osteoporosis

NCT ID: NCT00718224 Completed - Clinical trials for Venous Thromboembolism

Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Elective Knee Replacement Surgery

SAVE-KNEE
Start date: July 2008
Phase: Phase 3
Study type: Interventional

The primary objective was to compare the efficacy of Semuloparin sodium (AVE5026) with Enoxaparin for the prevention of Venous Thromboembolic Events [VTE] in patients undergoing elective knee replacement surgery. The secondary objectives were to evaluate the safety of AVE5026 in patients undergoing elective knee replacement surgery, and to document AVE5026 exposure in this population.

NCT ID: NCT00718068 Completed - Clinical trials for Arrhythmias, Cardiac

Safety of Continuous Potassium Chloride Infusion in Critical Care

ASPIC
Start date: October 2008
Phase: Phase 4
Study type: Interventional

Patients in critical care often require supplemental potassium chloride if levels in their blood are below acceptable level. Common practice is to administer a single dose of potassium chloride under controlled conditions via a drip, before checking if a further dose is required. The purpose of this study is to ensure that it is safe to administer potassium chloride continuously with the dose varied according to patient needs.